Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 16/20 | 0.66 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.66 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.66 |
| ▸ | PPARG | P37231 | 2/20 | 0.66 |
| ▸ | PPARD | Q03181 | 2/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.66 |
| ▸ | TP53 | P04637 | 1/20 | 0.66 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13456513 | 0.93 | ADORA3 (0.65) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL13429441 | 0.93 | ADORA3 (0.65) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL3232562 | 0.92 | ADORA3 (0.67) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL13429430 | 0.91 | ADORA3 (0.66) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL13456536 | 0.91 | ADORA3 (0.66) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL14310366 | 0.91 | ADORA3 (0.66) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL13456537 | 0.90 | ADORA3 (0.75) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL13429434 | 0.90 | ADORA3 (0.75) | ADORA3ADORA1ADORA2AHTR2CHTR2B | |
| SCHEMBL13456538 | 0.85 | ADORA3 (0.79) | ADORA3ADORA1ADORA2APPARGPPARD | |
| SCHEMBL13429435 | 0.85 | ADORA3 (0.79) | ADORA3ADORA1ADORA2APPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100062994-A1 | Adenosine Receptor Antagonists | SANTARIS PHARMA A/S (DK) | 2010-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100062994-A1 | Adenosine Receptor Antagonists | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885ADORA1 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.